Pfizer Inc. (PFE) Tuesday settled its litigation against Teva Pharmaceuticals USA Inc., a part of Teva Pharmaceuticals Ltd. (TEVA), relating to Pfizer's patent covering the use of Viagra to treat erectile dysfunction (sildenafil citrate 25, 50, and 100 mg tablets), which expires in April 2020 (including pediatric exclusivity).
As a result of the settlement, Teva will be allowed to launch a generic version of Viagra in the United States on December 11, 2017, or earlier under certain circumstances.
Teva will pay Pfizer a royalty for a license to produce its generic version.
The terms of the settlement agreement are otherwise confidential.
Teva has received tentative approval from the U.S. Food and Drug Administration (FDA) for its generic version of Viagra.
For comments and feedback: editorial@rttnews.com